Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMPEL NEUROPHARMA, INC.

(IMPL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Impel NeuroPharma : to Host Virtual Key Opinion Leader Event on August 6, 2021

07/29/2021 | 08:01am EDT

SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel’s lead product candidate TRUDHESA™ and commercial insights and opportunities in the acute migraine market. The event will take place on Friday, August 6, 2021 at 1:00pm ET.

The event will feature presentations from guest speakers Dr. Wade Cooper, Director of Headache and Neuropathic Pain at the University of Michigan School of Medicine, Dr. Stewart Tepper, Director of Dartmouth Headache Center at the Geisel School of Medicine, Dr. Nada Hindiyeh, Assistant Professor of neurology and neurological systems at Stanford Medical School and Impel NeuroPharma management.

A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.

About Impel NeuroPharma

Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: christina.tartaglia@sternir.com

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com


Primary Logo

Source: Impel NeuroPharma

2021 GlobeNewswire, Inc., source Press Releases

All news about IMPEL NEUROPHARMA, INC.
09/15IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $39 From $37, Maintains Outper..
MT
09/10Health Care Stocks Ail During Friday Trading
MT
09/10Health Care Stocks Ailing Friday
MT
09/10Wall Street Set for Gains as Biden-Xi Call Lifts Sentiment
MT
09/10IMPEL NEUROPHARMA : Prices Offering at $15 Per Share
MT
09/09IMPEL NEUROPHARMA : Announces Pricing of $45.0 Million Public Offering
AQ
09/09IMPEL NEUROPHARMA : Shares Rebound Amid Heavy Trading
MT
09/08WALL STREET STOCK EXCHANGE : Wall Street bogged down by Delta spread
09/08ANALYST RECOMMENDATIONS : Adobe, Broadcom, Chipotle Mexican Grill, Netflix, Vodafone...
09/07IMPEL NEUROPHARMA : Launches Stock Offering
MT
More news
Analyst Recommendations on IMPEL NEUROPHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 1,77 M - -
Net income 2021 -64,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,57x
Yield 2021 -
Capitalization 302 M 302 M -
Capi. / Sales 2021 171x
Capi. / Sales 2022 6,00x
Nbr of Employees 59
Free-Float 97,8%
Chart IMPEL NEUROPHARMA, INC.
Duration : Period :
Impel NeuroPharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMPEL NEUROPHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 13,43 $
Average target price 48,00 $
Spread / Average Target 257%
EPS Revisions
Managers and Directors
Adrian Adams Chairman, President & Chief Executive Officer
John Harold Leaman Chief Financial Officer
John D. Hoekman Chief Technology & Development Officer
Meghan Swardstrom Vice President-Clinical Development & Operations
Stephen Bevan Shrewsbury Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
IMPEL NEUROPHARMA, INC.0.00%287
MODERNA, INC.315.47%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.43.03%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-5.78%28 939